Data topics

Pharma incentive compensation analytics adds an intelligence layer on top of existing IC engines (Varicent, Xactly, Excel) so they don’t just calculate payouts, but actually explain them. The post dives into why reps build shadow spreadsheets—geographic inequity, data gaps, opaque plans, and risky Excel processes—and how AI + a semantic layer + conversational access + agentic workflows can investigate payout variance, monitor fairness, simulate plan changes, and catch data issues before statements go out. It also outlines practical use cases (automated variance investigation, fairness monitoring, scenario planning, data validation, plan simulation), a phased 9–13 month implementation approach, and the ROI metrics that show reduced disputes, faster resolution times, and higher rep trust.

Most pharma next-best-action programs promise AI-driven guidance for reps, but fall apart on bad data, missing context, and black-box models. This post breaks down why traditional NBA efforts stall, and what’s actually working: analytics-ready data products, a semantic layer that understands pharma metrics and entities, identity resolution to kill “ghost” HCPs, and agentic analytics that can investigate, validate, and recommend real next-best actions across HCP targeting, territory fairness, coaching, and omnichannel orchestration.

Pharma brand and commercial insights teams are stuck in the 5-system shuffle, Excel export hell, and a constant speed-versus-rigor tradeoff. This practical guide explains how agentic analytics, a pharma-aware semantic layer, and AI agents transform brand analytics—unifying IQVIA, Symphony, Veeva, and internal data, offloading grunt work, and delivering fast, defensible answers that actually shape brand strategy.

When pharma brands strike major deals, they don’t just gain access—they inherit complex tradeoffs. From navigating volume vs. margin to managing payer fatigue, these tradeoffs shape strategy long after contracts are signed. This blog breaks down five recurring tensions in market access and shows how AI-powered analytics helps commercial and HEOR teams model scenarios, simulate outcomes, and move from rigid strategy to adaptive execution.

Too often, commercial pharma reps are working from outdated, imprecise target lists—wasting time on the wrong doctors while missing key growth opportunities. This blog explores how Tellius transforms field sales by turning fragmented data into real-time, physician-level insights. Learn how natural language querying, AI-powered drop lists, and dynamic segmentation help teams respond faster, optimize territory planning, and drive impact at the moment of decision—not just at the end of the quarter.

With the FDA’s landmark approval of CAR-T therapies like Abecma and Carvykti as earlier-line treatments, the commercial landscape is shifting rapidly. This blog explores the next phase of CAR-T market access and the analytics brand teams need to navigate it. Learn how to forecast pull-through, identify high-opportunity accounts, and guide sales execution using real-world data, segmentation strategies, and AI-powered insights. From payer dynamics to provider referral patterns, find out what it takes to win in a competitive, high-cost therapeutic space.

Faster drug approvals are coming. Here's how field sales, market access, and brand teams must adapt—and why AI analytics is no longer optional.

The path from dashboard sprawl to true self-service isn't just about better technology—it's about unlocking your team's ability to act on insights in real-time. While traditional BI tools force pharma teams into endless workarounds, AI-powered platforms like Tellius are purpose-built for the complexity, compliance requirements, and speed demands of commercial pharma.

Key learnings from Novo Nordisk to help you along your journey to unlocking business value with AI in the commercial pharmaceutical space.

With Snowflake’s powerful AI Data Cloud as the foundation, Tellius adds the magic of conversational AI, automated insights, live Vizpads, and predictive analytics.

Learn how Novo Nordisk’s commercial analytics team is leveraging Tellius' AI analytics solution to drive data-driven answers and insights.

During a PMSA 2024 Q&A session, leaders from Novartis, Pfizer, UCB Biopharma, and Boehringer-Ingelheim covered the current state of GenAI and its immense potential to transform the pharmaceuticals industry. So, what's in store?

Learn how AI-powered approaches to pharmaceutical and biotech pricing, contracting, rebates, and revenue management are helping commercial and market access teams navigate common challenges.

Pharmacyclics, an AbbVie company, sought to empower more members of its commercial team to make better and faster data-driven decisions. The IT team used Tellius to up their analytics game.

Implementing AI-driven analytics is a catalyst for transformative change in the pharmaceutical and life sciences world.

Market access teams at pharmaceutical & life science organizations are critical to commercial success. Here's how AI-powered approaches can help.

Tellius has announced a partnership with Indegene, a technology-led healthcare solutions provider. The partnership will leverage Indegene’s deep domain knowledge in life sciences and expertise in advanced data and analytics, empowering companies with data at scale and AI-driven analytics that enable faster and better business decisions.

This post showcases how Tellius can be leveraged to more easily perform an analysis of a drug’s commercial performance using 3rd party pharmaceutical sales data combined with internal sales and operations data.

Humans are curious, collaborative, and intelligent. Our business systems are the exact opposite — they require us to think and communicate more like a machine to get what we want. To answer the question posited earlier, this gentleman’s BI experience was likely lacking humanity.

Healthcare organizations adopting a data-driven culture are set to derive major benefits in terms of improving care to patients and...

Doctors are pretty smart people, and it’s not a lack of want that historically denied them better insights to their...